Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H19NO2 |
Molecular Weight | 173.2527 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H](C)C[C@H](N)CC(O)=O
InChI
InChIKey=JXEHXYFSIOYTAH-SFYZADRCSA-N
InChI=1S/C9H19NO2/c1-3-4-7(2)5-8(10)6-9(11)12/h7-8H,3-6,10H2,1-2H3,(H,11,12)/t7-,8+/m1/s1
Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00738738
Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Imagabalin
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
300000034200
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
10236037
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
DTXSID00976534
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
UU-111
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
DB12105
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
NDG6931B7H
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
610300-07-7
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
C83785
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
9126
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103836
Created by
admin on Sat Dec 16 17:02:33 GMT 2023 , Edited by admin on Sat Dec 16 17:02:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)